期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙格列汀联合二甲双胍治疗2型糖尿病的临床疗效及安全性研究 被引量：6

下载PDF
导出
摘要 目的沙格列汀联合二甲双胍治疗2型糖尿病的临床疗效及安全性。方法将2012年3月至2014年3月南京市红十字医院收治的80例2型糖尿病患者随机分为对照组和治疗组,每组各40例,对照组应用二甲双胍治疗,治疗组予以沙格列汀联合二甲双胍治疗,治疗24周,观察两组患者空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、胆固醇(TC)、低密度脂蛋白(LDL)、体质量指数(BMI)及胰岛β细胞功能指数(HOMA-β),胰岛素抵抗指数(HOMA-IR)等方面的变化。结果治疗组治疗后FPG、PPG、HbA1c、TC、LDL相较于对照组显著下降(P<0.05),治疗组治疗后胰岛β细胞功能指数明显升高(P<0.05),胰岛素抵抗指数明显下降(P<0.05),两组治疗后BMI差异无统计学意义(P>0.05)。结论沙格列汀联合二甲双胍能更好的控制血糖,改善患者的血脂,减少低血糖的发生率,不增加体质量,降糖安全有效。
作者 董丽
机构地区 南京市红十字医院内分泌科
出处 《中国医药指南》 2014年第28期117-118,共2页 Guide of China Medicine
关键词 DPP-4抑制剂 二甲双胍 2型糖尿病
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献12

  • 1宁光.肠促胰素在血糖稳态调节和2型糖尿病治疗中的作用[J].中华内分泌代谢杂志,2010,26(9):836-839. 被引量：24
  • 2Janardhan S,Sastry GN.Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment [J].Curr Drug Targets,201 4,15(6):600-621.
  • 3Defronzo RA,Hissa MN.The efficacy and safety of saxagliptin when added to metformiri therapy in patients[J].Diabetes Care,2009,32(9): 1649-1655.
  • 4Nauck MA,Ellis GC.Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy:a multicentre,randomised,double-blind[J].Int J Clin Pract,2009, 63(1):46-45.
  • 5Fass AD1,Gershman JA.Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination[J].Adv Ther,2013, 30(4):337-353.
  • 6White JL,Buchanan P.A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy[J].BMC Endocr Disord,2014,14(1):17.
  • 7Aroda VR,Henry RR.Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors[J].Clin Ther,2012,34(6):1247-1258.
  • 8Esposito K,Cozzolino D.Dipeptidyl peptidase-4 inhibitors and HbAlc target of <7% in type 2 diabetes: rneta-analysis[J]. Diabetes Obes Metab,2011,13(7):594-603.
  • 9Lindsay JR,Dully NA.Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes[J].Diabet Med,2005,22(5):654-657.
  • 10Shah Z,Kampfrath T.Long-Term dipeptidyl peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment[J].Circulation,2011,124(21):2338-2349.

二级参考文献33

  • 1Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512.
  • 2Ugleholdt R,Zhu X,Deacon CF,et al.Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.Endocrinology,2004,145:1349-1355.
  • 3Holst JJ.Glucagon and glucagon-like peptides 1 and 2.Results Probl Cell Diffe,2010,50:121-135.
  • 4Doyle ME,Egan JM.Mechanisms of action of glucagon-like peptide 1 in the pancreas.Pharmacol Ther,2007,113:546-593.
  • 5Baggio LL,Drucker DJ.Biology of incretins:GLP-1 and GIP.Gastroenterology,2007,132:2131-2157.
  • 6Herrmann C,Goke R,Richter G,et al.Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.Digestion,1995,56:117-126.
  • 7Anini Y,Brubaker PL.Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells.Endocrinology,2003,144:3244-3250.
  • 8De Leon DD,Crutchlow MF,Ham JY,et al.Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.Int J Biochem Cell Biol,2006,38:845-859.
  • 9Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus.Korean Diabetes J,2010,34:2-9.
  • 10Nauck MA,Heimesaat MM,Behle K,et al.Effects of glucagon-like peptide 1 on counterregulatory hormone responses,cognitive functions,and insulin secretion during hyperinsulinemic,stepped hypoglycemic clamp experiments in healthy volunteers.J Clin Endocrinol Metab,2002,87:1239-1246.

共引文献23

同被引文献54

  • 1宋燕庆.二甲双胍联合沙格列汀与二甲双胍单药治疗2型糖尿病疗效比较[J].兵团医学,2013(4):18-19. 被引量：2
  • 2Barnett AH,Charbonnel B,Moses RG,et al.Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus[J].Curr Med Res Opin,2015;31(10):1919-31.
  • 3Scirica BM,Braunwald E,Raz I,et al.Heart failure,saxagliptin,and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized tria[J].Circulation,2015;132(6):e120.
  • 4Matthaei S,Catrinoiu D,Celiński A,et al.Randomized,double-blind tria of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes[J].Diabetes Care,2015;38(11):2018-24.
  • 5DeF ronzo RA,Hissa MN,Garber AJ,et al.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inad-equately controlled type 2 diabetes with metformin alone[J].Diabetes Care,2009;32(9):1649-55.
  • 6Jadzinsky M,Pfutzner A,Paz-Pacheco E,et al.Saxagliptin given in combination with metformin as initial therapy improves glycae-mic control in patients with type 2 diabetes compared with either monotherapy:A randomized controlled tria[lJ].Diabet Obes Metab,2009;11(6):611-22.
  • 7Yang W,Pan CY,Tou C,et al.Efficacy and safety saxagliptin added to metformin in Asian people with type 2 diabetes melitus:a randomized contrrolled tria[lJ].Diabet Res Clin Pract,2011;94(2):217-24.
  • 8Mosenzon O,Wei C,Davidson J,et al.Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial[J].Diabetes Care,2015;38(11):2142-50.
  • 9Pech V,Abusaada K,Alemany C.Dipeptidyl peptidase-4 inhibition may stimulate progression of carcinoid tumor[J].Case Rep Endocrinol,2015;2015(1):952019.
  • 10Mathieu C,Ranetti AE,Li D,et al.Randomized,double-blind,phase 3trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes[J].Diabetes Care,2015;38(11):2009-17.

引证文献6

二级引证文献96

中国医药指南
2014年 第28期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部